Please assess the completion status of the following clinical trial:

Trial Title: Rituximab for Prevention of Chronic GVHD

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients who have undergone either ablative or non-myeloablative allogeneic stem cell transplantation~* Peripheral blood stem cells must have been used as the stem cell source~* Patients must have received transplantation from donors who are identical at 6 HLA loci, or mismatched at no more than 1 locus.~* Patients who have undergone a non-myeloablative stem cell transplant must have \> 80% donor hematopoiesis within 30 days of study enrollment~* 18 years of age or older~* Performance Status 0-2~* Life expectancy of \> 100 days~* Subjects with CLL are eligible, if there is no more than 20% residual leukemia in the bone marrow at the time of study entry~Exclusion Criteria:~* Evidence of relapsed or residual malignancy within 30 days of trial entry~* Highly aggressive B cell malignancy, such as Burkitt's lymphoma or Burkitt's-like lymphoma~* Allogeneic stem cell transplantation using a single or multiple umbilical cord blood units or using bone marrow~* Evidence of any active uncontrolled infection, or evidence of natural exposure to Hepatitis B, Hepatitis C or HIV~* Evidence of ongoing gastrointestinal or hepatic acute GVHD, or evidence of greater than ongoing Stage I cutaneous acute GVHD~* GVHD with chronic features diagnosed prior to day +100 or prior to enrollment~* Participation in a clinical trial evaluating another preventative strategy for chronic GVHD, or ongoing participation in a clinical trial for therapy of acute GVHD~* No Donor Lymphocyte Infusion (DLI) prior to day 100 and not plans for a DLI in the upcoming 30 days~* Heart failure uncontrolled by medications~* Pregnancy or lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).